These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32264972)

  • 21. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
    Gabay C; Msihid J; Zilberstein M; Paccard C; Lin Y; Graham NMH; Boyapati A
    RMD Open; 2018; 4(1):e000607. PubMed ID: 29556418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
    Lamb YN; Deeks ED
    Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
    Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.
    Fournier M; Chen CI; Kuznik A; Proudfoot C; Mallya UG; Michaud K
    Clinicoecon Outcomes Res; 2019; 11():117-128. PubMed ID: 30787625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
    Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
    Taylor PC; Schiff MH; Wang Q; Jiang Y; Zhuang Y; Kurrasch R; Daga S; Rao R; Tak PP; Hsu B
    Ann Rheum Dis; 2018 May; 77(5):658-666. PubMed ID: 29483080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.
    Burmester GR; Bykerk VP; Buch MH; Tanaka Y; Kameda H; Praestgaard A; van Hoogstraten H; Fernandez-Nebro A; Huizinga T
    Rheumatology (Oxford); 2022 May; 61(6):2596-2602. PubMed ID: 34508594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis.
    Ma L; Xu C; Paccaly A; Kanamaluru V
    Clin Pharmacokinet; 2020 Nov; 59(11):1451-1466. PubMed ID: 32451909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; van Hoogstraten H; Mangan E; Carita P; Huynh TM
    Adv Ther; 2019 Apr; 36(4):817-827. PubMed ID: 30864105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to Adalimumab.
    Curtis JR; Aletaha D; Burmester G; Ford K; van Hoogstraten H; Praestgaard A; Bykerk VP;
    J Clin Rheumatol; 2023 Jun; 29(4):196-201. PubMed ID: 36858816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).
    Tanaka Y; Takahashi T; van Hoogstraten H; Kato N; Kameda H
    Mod Rheumatol; 2024 Jul; 34(4):670-677. PubMed ID: 37606691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
    Rehberg M; Giegerich C; Praestgaard A; van Hoogstraten H; Iglesias-Rodriguez M; Curtis JR; Gottenberg JE; Schwarting A; Castañeda S; Rubbert-Roth A; Choy EHS;
    Rheumatol Ther; 2021 Dec; 8(4):1661-1675. PubMed ID: 34519964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.
    Choy E; Bykerk V; Lee YC; van Hoogstraten H; Ford K; Praestgaard A; Perrot S; Pope J; Sebba A
    Rheumatology (Oxford); 2023 Jul; 62(7):2386-2393. PubMed ID: 36413080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
    Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.